The 31-gene expression profile test for cutaneous melanoma identifies patients with stage IB- IIA disease who have recurrence risk similar to that of stage IIB-IIC disease

Background: Many patients with stage IB-IIA cutaneous melanoma (CM) recur and die from their disease. Stage IIB–IIC patients are eligible for adjuvant immunotherapy, while those with stage IB– IIA are not. Identifying which stage IB-IIA patients are likely to recur could select for patients who may benefit from adjuvant treatment and lead to improved outcomes. The integrated 31-gene expression profile test (i31-GEP) provides a precise risk of recurrence prediction to identify patients at high risk of recurrent CM.